Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$144.31

0.08 (0.06%)

, CLVS

Clovis

$59.97

0.27 (0.45%)

09:45
06/19/17
06/19
09:45
06/19/17
09:45

Raymond James remains cautious on Tesaro, takeout less likely

Raymond James analyst Christopher Raymond remains cautious on Tesaro (TSRO) shares following Clovis' (CLVS) Rubraca ARIEL3 results. The analyst said PFS measures between the Clovis Rubraca and Tesaro's Zejula are remarkably similar among ovarian cancer patients, making the PARP space much more competitive and crowded. Raymond believes a takeout of Tesaro based on Zejula's superior labeling is much less likely and reiterated his Market Perform rating on shares.

TSRO

Tesaro

$144.31

0.08 (0.06%)

CLVS

Clovis

$59.97

0.27 (0.45%)

  • 30

    Jun

TSRO Tesaro
$144.31

0.08 (0.06%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/16/17
FBCO
06/16/17
NO CHANGE
Target $88
FBCO
Outperform
Clovis price target raised to $88 from $74 at Credit Suisse
Credit Suisse analyst Alethia Young assumed coverage of Clovis Oncology (CLVS) and raised the firm's price target on the stock to $88 from $74, noting that her 2023 U.S. estimate for rucaparib is $1.3B versus prior coverage's forecast of $700M. Young, who thinks that the PARPi market is big enough that both Clovis and Tesaro (TSRO) can have blockbuster products, believes both companies are likely attractive targets for large global pharma companies, she tells investors. The analyst keeps an Outperform rating on Clovis shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Outperform
Clovis should now be 'prime takeout candidate,' says Leerink
Leerink analyst Michael Schmidt views this morning's data from Clovis Oncology (CLVS) as the "best-case outcome." The data indicate that efficacy of the three leading PARP inhibitors look very comparable, Schmidt tells investors in a research note titled "Bull Case Plays Out as ARIEL3 Hits All Endpoints." Tesaro (TSRO) and AstraZeneca (AZN) own the other leading PARP inhibitors. The analyst expects shares of Clovis to "trade up significantly" on today's news. Clovis shares in premarket trading are up 40%, or $24.03, to $84.00. "With best-case data in hand," Clovis should be a "prime takeout candidate," Schmidt tells investors. He reiterates an Outperform rating on the shares.
06/19/17
LEER
06/19/17
NO CHANGE
LEER
Market Perform
Clovis reported similar efficacy to Tesaro's Zejula, says Leerink
Leerink analyst Seamus Fernandez says the top-line efficacy data announced this morning for Clovis Oncology's (CLVS) Phase 3 Ariel3 trial of its PARP inhibitor Rubraca "were broadly similar" to that seen in Tesaro's (TSRO) Nova trial of Zejula across all patient population in second-line or greater ovarian cancer maintenance. This adds "considerable weight" to the argument that all three of these PARP inhibitors have similar activity, Fernandez tells investors in a research note. The analyst keeps a Market Perform rating on Tesaro shares.
CLVS Clovis
$59.97

0.27 (0.45%)

06/19/17
CHDN
06/19/17
UPGRADE
CHDN
Neutral
Clovis upgraded to Neutral from Sell at Chardan
06/19/17
STFL
06/19/17
NO CHANGE
Target $125
STFL
Buy
Clovis price target raised to $125 from $86 at Stifel

TODAY'S FREE FLY STORIES

NHYDY

Norsk Hydro

$7.60

-0.16 (-2.06%)

07:43
01/17/18
01/17
07:43
01/17/18
07:43
Downgrade
Norsk Hydro rating change  »

Norsk Hydro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAST

Fastenal

$55.44

-0.15 (-0.27%)

07:43
01/17/18
01/17
07:43
01/17/18
07:43
Earnings
Fastenal reports Q4 EPS 45c ex-tax benefit, consensus 45c »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LBTYA

Liberty Global

$36.56

-0.31 (-0.84%)

07:43
01/17/18
01/17
07:43
01/17/18
07:43
Upgrade
Liberty Global rating change  »

Liberty Global upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

07:42
01/17/18
01/17
07:42
01/17/18
07:42
Recommendations
Juno Therapeutics, Celgene analyst commentary  »

Juno Therapeutics price…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:42
01/17/18
01/17
07:42
01/17/18
07:42
Hot Stocks
Goldman CEO: Global economy poised to accelerate, tax reform providing tailwinds »

"Last year, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

ONTX

Onconova

$1.74

-0.0901 (-4.92%)

07:42
01/17/18
01/17
07:42
01/17/18
07:42
Hot Stocks
Onconova increases sample size in Phase 3 INSPIRE pivotal trial in MDS »

Onconova is moving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HALO

Halozyme

$19.74

-0.62 (-3.05%)

07:41
01/17/18
01/17
07:41
01/17/18
07:41
Technical Analysis
Technical Take: Halozyme drops in pre-market »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

07:41
01/17/18
01/17
07:41
01/17/18
07:41
Conference/Events
UBS oil services analyst holds an analyst/industry conference call »

Oil Services Analyst Wong…

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:41
01/17/18
01/17
07:41
01/17/18
07:41
Hot Stocks
Goldman Sachs reports Basel III CET1 ratio of 10.9% at December 31 »

The firm's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

C

Citi

$77.11

0.27 (0.35%)

07:40
01/17/18
01/17
07:40
01/17/18
07:40
Recommendations
Citi analyst commentary  »

Citi price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 24

    Jan

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:38
01/17/18
01/17
07:38
01/17/18
07:38
Hot Stocks
Goldman Sachs reports Q4 net revenue in FICC sales & trading $1B »

Net revenues in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

SIG

Signet Jewelers

$56.79

-0.15 (-0.26%)

07:38
01/17/18
01/17
07:38
01/17/18
07:38
Periodicals
U.S. judge excludes 70,000 women from Sterling Jewelers lawsuit, Reuters says »

A U.S. judge has excluded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:37
01/17/18
01/17
07:37
01/17/18
07:37
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs »

Goldman Sachs says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

GG

Goldcorp

$15.39

1.04 (7.25%)

07:37
01/17/18
01/17
07:37
01/17/18
07:37
Downgrade
Goldcorp rating change  »

Goldcorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Earnings
Goldman Sachs reports Q4 EPS $5.68 ex Tax Legislation, consensus $4.92 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

UNH

UnitedHealth

$232.90

4.26 (1.86%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGHT

8x8, Inc.

$15.30

0.05 (0.33%)

, RNG

RingCentral

$50.65

-1.7 (-3.25%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Upgrade
8x8, Inc., RingCentral rating change  »

8x8, Inc. upgraded to…

EGHT

8x8, Inc.

$15.30

0.05 (0.33%)

RNG

RingCentral

$50.65

-1.7 (-3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 25

    Jan

ORCL

Oracle

$49.59

0.08 (0.16%)

, PBR

Petrobras

$11.70

0.23 (2.01%)

07:35
01/17/18
01/17
07:35
01/17/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

ORCL

Oracle

$49.59

0.08 (0.16%)

PBR

Petrobras

$11.70

0.23 (2.01%)

AMAT

Applied Materials

$54.50

1.05 (1.96%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KMI

Kinder Morgan

$19.39

-0.13 (-0.67%)

KODK

Kodak

$8.50

-0.7 (-7.61%)

MGM

MGM Resorts

$36.03

1 (2.85%)

PX

Praxair

$162.10

-2.05 (-1.25%)

PVG

Pretium Resources

$11.65

0.5 (4.48%)

PAAS

Pan American Silver

$17.24

0.58 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 21

    Feb

  • 25

    Mar

07:35
01/17/18
01/17
07:35
01/17/18
07:35
General news
U.S. MBA mortgage market index rose 4.1% »

U.S. MBA mortgage market…

07:33
01/17/18
01/17
07:33
01/17/18
07:33
Conference/Events
Federal Reserve Bank of Cleveland President speaks on monetary policy »

Cleveland Federal Reserve…

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

, AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

07:33
01/17/18
01/17
07:33
01/17/18
07:33
Conference/Events
Strongbridge Biopharma to host conference call »

Conference call to…

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

XRAY

Dentsply Sirona

$65.65

-0.14 (-0.21%)

07:32
01/17/18
01/17
07:32
01/17/18
07:32
Hot Stocks
Dentsply Sirona appoints Donald Casey Jr. as CEO »

Dentsply Sirona announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Conference/Events
Federal Reserve Bank of Dallas President participates in a discussion »

Dallas Federal Reserve…

LCII

LCI Industries

$123.65

-2.75 (-2.18%)

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Hot Stocks
LCI Industries to acquire Taylor Made Group, terms not disclosed »

LCI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNHI

CNH Industrial

$14.72

-0.21 (-1.41%)

07:31
01/17/18
01/17
07:31
01/17/18
07:31
Initiation
CNH Industrial initiated  »

CNH Industrial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.